CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 2.7% – What’s Next?

CRISPR Therapeutics AG (NASDAQ:CRSP) shares traded down 2.7% during trading on Monday . The company traded as low as $41.14 and last traded at $42.23. 609,124 shares changed hands during trading, a decline of 70% from the average session volume of 1,997,774 shares. The stock had previously closed at $43.42.

Wall Street Analyst Weigh In

CRSP has been the subject of a number of recent research reports. Chardan Capital reiterated a “buy” rating and issued a $94.00 target price on shares of CRISPR Therapeutics in a research note on Tuesday, December 10th. Royal Bank of Canada restated a “sector perform” rating and issued a $53.00 target price on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. JMP Securities reaffirmed a “market outperform” rating and set a $86.00 price target on shares of CRISPR Therapeutics in a research note on Friday, December 20th. Needham & Company LLC reissued a “buy” rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday, January 14th. Finally, Barclays dropped their target price on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 6th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $78.38.

CRISPR Therapeutics Price Performance

The stock’s fifty day simple moving average is $44.09 and its two-hundred day simple moving average is $47.46. The company has a market capitalization of $3.52 billion, a price-to-earnings ratio of -14.56 and a beta of 1.68.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.41. The firm had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same quarter last year, the company posted ($1.41) earnings per share. On average, sell-side analysts predict that CRISPR Therapeutics AG will post -5.13 EPS for the current year.

Insider Buying and Selling

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $55.10, for a total transaction of $826,500.00. Following the completion of the transaction, the chief executive officer now directly owns 181,540 shares of the company’s stock, valued at $10,002,854. The trade was a 7.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Hedge funds have recently made changes to their positions in the business. Wilmington Savings Fund Society FSB bought a new position in CRISPR Therapeutics in the 3rd quarter valued at about $40,000. Darwin Wealth Management LLC acquired a new stake in shares of CRISPR Therapeutics in the 3rd quarter worth approximately $43,000. Highline Wealth Partners LLC bought a new position in shares of CRISPR Therapeutics in the fourth quarter valued at approximately $39,000. Western Pacific Wealth Management LP lifted its holdings in shares of CRISPR Therapeutics by 100.0% in the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after buying an additional 500 shares during the period. Finally, Eastern Bank bought a new position in CRISPR Therapeutics during the third quarter valued at about $70,000. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.